General Biotechnology

In the fiercely competitive world of biopharmaceuticals, the race to dominate the biologic market is more intense than ever. With blockbuster biologics generating billions in revenue, securing market exclusivity isn’t just a strategic advantage—it’s a …

In the high-stakes world of pharmaceutical investing, innovation is often viewed through the lens of patents—those legal shields that protect new drugs and justify hefty valuations. But what if the next wave of opportunity isn’t just about securing pat…

In the high-stakes world of pharmaceutical innovation, clinical trial results often steal the spotlight. But beneath the surface lies a strategic goldmine that can make or break an investor’s confidence: drug patent portfolios. For institutional invest…

In today’s rapidly evolving healthcare landscape, pharmaceutical procurement stands at a critical crossroads. The decision between prioritizing brand-name drugs versus generics isn’t just a matter of cost—it’s a strategic move that can significantly im…

In the high-stakes world of pharmaceutical innovation, the battle over patents isn’t just about protecting intellectual property — it’s about shaping the future of healthcare and access to life-saving medicines. Recently, a landmark legal dispute betwe…

In the high-stakes world of pharmaceutical innovation, the battle over patents isn’t just a legal skirmish—it’s a defining moment that can shape the future of healthcare and industry giants alike. Recently, Bristol-Myers Squibb’s legal challenge agains…

In the high-stakes world of pharmaceutical innovation, the battle over patents isn’t just about legal rights — it’s about shaping the future of healthcare and access to life-saving medicines. Recently, a landmark case has emerged that underscores the i…

In the high-stakes world of pharmaceutical innovation, the battle over generic drug approvals is fierce—and increasingly complex. As patent litigations become more strategic and multifaceted, companies must navigate a labyrinth of legal maneuvers to pr…

In the high-stakes world of healthcare, few issues are as contentious—and consequential—as the intersection of drug patent strategies and government programs designed to expand access. The recent analysis titled "The Collision of Mandate and Monop…

In today’s rapidly evolving pharmaceutical landscape, the rules of the game are changing — and if your company isn’t adapting quickly, you risk falling behind. The recent shifts in generic drug portfolio management are not just minor tweaks; they repre…